Snapshot from Sep 14, 2026 at 07:00 UTC. For live data and tracking: View Live
Business private placement

Quoin Pharmaceuticals $50M Private Placement

Analysis based on 6 articles · First reported Aug 28, 2026 · Last updated Aug 28, 2026

Sentiment
20
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The private placement provides Quoin Pharmaceuticals with up to $50 million in funding, extending its cash runway into the second half of 2029 and supporting clinical development. This financing is likely to be viewed positively by investors, potentially supporting the company's stock price and reducing near-term dilution concerns.

Pharmaceuticals Biotechnology

Quoin Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, announced on August 28, 2026 that it entered into a securities purchase agreement with healthcare-focused institutional investors to raise up to approximately $50.0 million in gross proceeds. The financing includes initial upfront funding of approximately $30.8 million and up to an additional $19.2 million upon the cash exercise of ordinary warrants. The company will issue 6,305,300 American Depositary Shares (ADSs) and accompanying ordinary warrants at a combined purchase price of $4.88 per ADS and warrant. The warrants have an exercise price of $6.10 per ADS and expire five years from closing or 30 days after the primary endpoint is met in the company's clinical trial CL-QRX003-004 for Netherton Syndrome. The private placement is expected to close on or about August 31, 2026. Proceeds will be used for general corporate purposes, including R&D and completion of clinical development of QRX003. The company expects the net proceeds to fund operations into the second half of 2029. Leerink Partners acted as lead placement agent, with BTIG and Lake Street Capital Markets as co-placement agents. The company has agreed to file a registration statement with the SEC for the resale of the securities.

100 Quoin Pharmaceuticals entered into agreement
90 Quoin Pharmaceuticals issued ADSs and warrants
60 Leerink Partners acted as lead placement agent Quoin Pharmaceuticals
50 BTIG acted as co-placement agent Quoin Pharmaceuticals
50 Lake Street Capital Markets acted as co-placement agent Quoin Pharmaceuticals
stock
Quoin Pharmaceuticals is the issuer in this private placement, raising up to $50 million to fund operations and clinical development. The financing strengthens its balance sheet and extends its cash runway into 2029.
Importance 100.0 Sentiment 40.0
priv
Leerink Partners acted as lead placement agent for the private placement, facilitating the transaction and earning fees.
Importance 30.0 Sentiment 10.0
priv
RA Capital Management is a participating investor in the private placement, providing capital to Quoin Pharmaceuticals.
Importance 20.0 Sentiment 10.0
priv
Vibra Healthcare is a participating investor in the private placement, providing capital to Quoin Pharmaceuticals.
Importance 20.0 Sentiment 10.0
priv
AIGH Capital Management, LLC is a participating investor in the private placement, providing capital to Quoin Pharmaceuticals.
Importance 20.0 Sentiment 10.0
priv
Nantahala Capital Management is a participating investor in the private placement, providing capital to Quoin Pharmaceuticals.
Importance 20.0 Sentiment 10.0
priv
StemPoint Capital is a participating investor in the private placement, providing capital to Quoin Pharmaceuticals.
Importance 20.0 Sentiment 10.0
priv
Stonepine Capital Management is a participating investor in the private placement, providing capital to Quoin Pharmaceuticals.
Importance 20.0 Sentiment 10.0
priv
BTIG acted as co-placement agent for the private placement, assisting in the transaction.
Importance 20.0 Sentiment 10.0
priv
Lake Street Capital Markets acted as co-placement agent for the private placement, assisting in the transaction.
Importance 20.0 Sentiment 10.0
govactor
The SEC will receive a registration statement from Quoin Pharmaceuticals for the resale of the securities issued in the private placement.
Importance 15.0 Sentiment 0.0
exch
Nasdaq is the exchange on which Quoin Pharmaceuticals' ADSs are listed; the company must comply with Nasdaq rules regarding the minimum price.
Importance 10.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.